Veno-venous extracorporeal membrane oxygenation bridging to pharmacotherapy in pulmonary arterial hypertensive crisis

J Heart Lung Transplant. 2010 Jul;29(7):811-3. doi: 10.1016/j.healun.2010.02.005. Epub 2010 Apr 22.

Abstract

We report the case of a treatment-naive patient with pulmonary arterial hypertension who presented with decompensated right ventricular failure and cardiogenic shock. Unstable hemodynamics, hypoxia and end-organ hypoperfusion limited up-titration of pharmacotherapy. Mechanical circulatory support with veno-venous extracorporeal membrane oxygenation (VV-ECMO) was initiated to permit dose titration of pulmonary vasodilator therapy. VV-ECMO was weaned after 10 days of support, with successful transition to intravenous epoprostenol and oral sildenafil.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adult
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / therapeutic use
  • Combined Modality Therapy
  • Epoprostenol / administration & dosage
  • Epoprostenol / therapeutic use*
  • Extracorporeal Membrane Oxygenation / methods*
  • Female
  • Humans
  • Hypertension, Pulmonary / therapy*
  • Injections, Intravenous
  • Piperazines / administration & dosage
  • Piperazines / therapeutic use*
  • Purines / administration & dosage
  • Purines / therapeutic use
  • Shock, Cardiogenic / therapy
  • Sildenafil Citrate
  • Sulfones / administration & dosage
  • Sulfones / therapeutic use*
  • Treatment Outcome
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / therapeutic use
  • Ventricular Dysfunction, Right / therapy

Substances

  • Antihypertensive Agents
  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate
  • Epoprostenol